Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis

Prurigo Nodularis Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT00532519
• Other study ID #: horcoop-hmo-ctil
• Status: Not yet recruiting
• Phase: N/A
• First received: September 19, 2007
• Last updated: September 19, 2007

Study information

• Verified date: September 2007
• Source: Hadassah Medical Organization
• Contact: Liran Horev, MD
• Phone: OO97226777111
• Email: LIRAN_CH[@]BEZEQINT.NET
• Is FDA regulated: No
• Health authority: Israel: Israeli Health Ministry Pharmaceutical Administration
• Study type: Interventional

Clinical Trial Summary

Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless, in many cases no underlying physical disease is present. According to the literature, in fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform disorders.

We hypothesize that a group of these patients may benefit from antidepressant therapy.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 0
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• prurigo nodularis

• age: 18-70 years

• agreed to participate

Exclusion Criteria:

• younger than 18 or older than 70

• pregnant or lactating women

• chronic diseases: cancer, neurological disorders, diseases that are known to be associated with pruritus such as liver cirrhosis, uremia, etc.

• sensitivity to cipralotam

• psychosis, bi-polar disorder, substance addiction, use of antidepressant in the previous year

• use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Neurodermatitis
• Prurigo
• Prurigo Nodularis

Intervention

Drug:
• citalopram (cipralex)
10-20 mg/day, for 12 weeks.

Locations

Country	Name	City	State
Israel	: Hadassah Medical Organization,	Jerusalem

Sponsors (1)

Lead Sponsor	Collaborator
Hadassah Medical Organization

Country where clinical trial is conducted

Israel,